Federal Health Director Sidelined Over Undisclosed Financial Stake in Menopause Startup

2026-10-29 politics

Washington, Thursday, 29 October 2026.
ARPA-H Director Alicia Jackson has been placed on leave after publicly endorsing an FDA policy shift while secretly holding over $115,000 in equity in a commercial beneficiary.

Conflict of Interest Surrounds HRT Policy Endorsement

Alicia Jackson, director of the Advanced Research Projects Agency for Health (ARPA-H), has been placed on administrative leave amid escalating scrutiny over her endorsement of a pivotal Food and Drug Administration (FDA) policy shift on hormone replacement therapies (HRT) while retaining financial stakes in a beneficiary company. On October 24, 2026, the Department of Health and Human Services (HHS) confirmed Jackson’s leave status in response to questions from Bloomberg Law regarding a limited conflict-of-interest waiver she sought [5]. ProPublica reported that Jackson, who founded the menopause telehealth platform Evernow, held between $115,002 and $300,000 in Evernow stock at the time of her endorsement, with additional undisclosed stock options [1]. The policy change, announced in November 2025, eliminated ‘black box’ warnings on HRTs, a decision Jackson publicly praised at an HHS press conference on October 29, 2026, calling it ‘a victory for women and science’ [6][alert! ‘Jackson’s endorsement occurred after the policy was already implemented; her public support coincided with renewed scrutiny’].

Financial Disclosures and Ethical Red Flags

Jackson’s financial disclosures reveal a complex web of potential conflicts. Beyond her Evernow holdings, she reported investments in Gameto Inc., which grew from $15,001–$50,000 in October 2025 to $50,001–$100,000 by August 2026 [1]. Her husband, Alex Jacobson, co-founded 137 Ventures, a venture capital firm managing over 60 funds, including at least 13 in which Jackson also held undisclosed stakes [1]. Jacobson’s portfolio includes $5 million to $25 million in Palantir Technologies stock, a company that secured a $19 million ARPA-H contract in 2026, followed by a renewal potentially worth $13.7 million [1]. Ethics experts, including Virginia Canter, a former White House and Securities and Exchange Commission (SEC) ethics lawyer, have condemned Jackson’s actions. Canter noted that Jackson’s financial interests in Evernow created an ‘obvious conflict of interest,’ stating that her public endorsement of the HRT policy while retaining these stakes ‘puts her within the zone of a potential violation’ [1].

Timeline of Events and Agency Response

The timeline of events underscores the gravity of the situation. Jackson was sworn in as ARPA-H director on October 20, 2025, overseeing a $1.5 billion budget [1]. The FDA’s expert panel had already recommended removing black box warnings on HRTs months before her appointment, but Jackson’s public endorsement of the policy shift at the October 29, 2026, press conference drew immediate backlash [1][4]. By October 27, 2026, HHS officials briefed ARPA-H staff on Jackson’s administrative leave, citing unresolved ethics clearance issues [4]. The HHS spokesperson’s statement on October 24, 2026, confirmed Jackson’s leave status, framing it as a temporary measure while the agency assesses the facts [5]. ProPublica’s October 29, 2026, report further highlighted broader ethical concerns within the HHS, including Health Secretary Robert F. Kennedy Jr.’s wife’s media company receiving $210,000 from MAHA Action [1].

Broader Implications and Congressional Oversight

The controversy has reignited debates over financial transparency and ethical accountability in federal agencies. Kedric Payne, vice president and general counsel at the Campaign Legal Center, criticized the lack of enforcement mechanisms to prevent conflicts of interest, stating that ‘Americans deserve to know whether their leaders are prioritizing the public good or focusing more on their personal financial gain’ [6]. Payne’s remarks reflect growing public skepticism, particularly as midterm elections approach on November 3, 2026 [6]. Senate candidate Abdul El-Sayed has already seized on the issue, criticizing HHS leadership ahead of the vote [6]. Meanwhile, the FDA’s acting chief, Kyle Diamantas, emphasized rare disease initiatives as a top priority during a public meeting on October 28, 2026, but the agency’s broader credibility faces challenges amid the unfolding scandal [8]. The HHS’s decision to grant ‘enforcement discretion’ to compounding pharmacies producing unapproved peptides on October 28, 2026, has further fueled concerns about regulatory consistency and oversight [6].

Sources

regulatory ethics conflict of interest